{"id":"W4402560337","doi":"10.1016/j.annonc.2024.08.1489","title":"1423P Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Ipsen; Cilag; Astellas Pharma; Eisai; National Institute for Health and Care Research; Servier; Moderna; Incyte; EUSA Pharma; Seagen; Gilead Sciences; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gastro-; Chemotherapy; Internal medicine; Adenocarcinoma; Metastatic adenocarcinoma; Oncology; Esophageal adenocarcinoma; Cancer; Disease; Reflux","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000199218,0.0002411909,0.001010809,0.000180315,0.0000430715,0.00001234798,0.000203735,0.00007506204,0.0007609784],"category_scores_gemma":[0.00009274157,0.0001736441,0.0001438426,0.0002498596,0.00009567155,0.0001598282,0.0001104093,0.00006808048,0.000003430642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000527985,"about_ca_system_score_gemma":0.0003966041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003613557,"about_ca_topic_score_gemma":0.0002925074,"domain_scores_codex":[0.9983816,0.00003871831,0.0006140561,0.0005013621,0.0001701079,0.0002941415],"domain_scores_gemma":[0.9986039,0.0003762401,0.0002188496,0.0005778035,0.00007247663,0.0001507067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1511833,0.003640547,0.0003633783,0.000295827,0.002444047,0.0002926569,0.0006933182,0.000006213935,0.0005335682,0.00008936327,0.0717214,0.7687364],"study_design_scores_gemma":[0.3168726,0.175513,0.001767683,0.0001467947,0.002213953,0.00003701827,0.0003306134,0.002922039,0.003813829,0.00054704,0.4956115,0.0002238522],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9624584,0.008790713,0.002493515,0.01992689,0.0006149266,0.002932514,0.002594762,0.00006800404,0.0001202961],"genre_scores_gemma":[0.9706453,0.005168424,0.01373039,0.001173122,0.0008272284,0.0001167253,0.004383624,0.0000623582,0.003892821],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7685125,"threshold_uncertainty_score":0.833218,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1966977244664351,"score_gpt":0.4561171381704844,"score_spread":0.2594194137040493,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}